MIXED MICELLES: ADVANCED NANOCARRIERS FOR PULMONARY MUCOLYTIC DRUG DELIVERY-A SYSTEMATIC SCOPING REVIEW
DOI:
https://doi.org/10.22159/ijap.2026v18i1.55866Keywords:
Bromhexine HCl, Nanocarrier, Nanomicelles, Pulmonary, SurfactantAbstract
This study is to summarize and analyze existing materials on advanced mixed micellar systems for the pulmonary transmission of mucolytic drugs. This review focuses on the composition and preparation of these compounds, their performance characteristics, and key obstacles slowing down clinical use for mucoreactive respiratory diseases. A systematic scoping a review of the scientific literature was conducted using PubMed and Scopus. We also searched in Embase. This review encompassed all sources from 2000 to 2024. Our searching strategy used key information related to mixed micelles, nanocarriers, delivery to lungs, mucolytics, and performance parameters. The review included original research papers, comparative studies, and other relevant reviews. Mixed micelles, which are usually 10 nm-100 nm in size, are conducive to pulmonary drug delivery. Combining polymers (e. g., Pluronics®) and surfactants (e. g., TPGS) results in high thermodynamic stability (low critical micelle concentration), high encapsulation efficiency for hydrophobic mucolytics like bromhexine HCl, and favorable mucus penetration. This is because of their small size and highly modifiable PEGylated surfaces. Thin-film hydration is a common method for preparing mixtures. Compared with liposomes, mixed micelles offer increased stability during nebulization and easier and more scalable manufacturing methods. Mixed micelles are a promising and highly adaptable nanocarrier system designed for delivering mucolytic agents to the lungs, as they facilitate significant elimination of mucus. The workable evidence from preclinical studies is strong. However, major translational gaps remain. Future research must be able to optimize systematically the formulations for specific mucolytics and carry out long-term safety and efficacy studies in vivo within relevant disease models. Researchers need to build the infrastructure for scalable, GMP-compliant production of these products to realize their potential to save lives.
References
1. Pellosi DS, D Angelo I, Maiolino S, Mitidieri E, D Emmanuele Di Villa Bianca R, Sorrentino R. In vitro/in vivo investigation on the potential of Pluronic® mixed micelles for pulmonary drug delivery. Eur J Pharm Biopharm. 2018;130:30-8. doi: 10.1016/j.ejpb.2018.06.006, PMID 29890256.
2. Sharma D, Ali AA, Trivedi R, Soni S, Ghelani T, Singh P. Polymeric micelles for pulmonary drug delivery: a comprehensive review. J Control Release. 2020;326:436-59. doi: 10.1016/j.jconrel.2020.07.031.
3. Hebbink GA, Janssen PH, Kok JH, Menarini L, Giatti F, Funaro C. Lubricant sensitivity of direct compression grades of lactose in continuous and batch tableting process. Pharmaceutics. 2023;15(11):2575. doi: 10.3390/pharmaceutics15112575, PMID 38004554.
4. Wang X, Wang Y, Tang T, Zhao G, Dong W, Li Q. Curcumin-loaded RH60/F127 mixed micelles: characterization biopharmaceutical characters and anti-inflammatory modulation of airway inflammation. Pharmaceutics. 2023;15(12):2710. doi: 10.3390/pharmaceutics15122710, PMID 38140051.
5. Kancharla S, Bedrov D, Tsianou M, Alexandridis P. Structure and composition of mixed micelles formed by nonionic block copolymers and ionic surfactants in water determined by small angle neutron scattering with contrast variation. J Colloid Interface Sci. 2022;609:456-68. doi: 10.1016/j.jcis.2021.10.176, PMID 34815085.
6. Rana AA, Yusaf A, Shahid S, Usman M, Ahmad M, Aslam S. Unveiling the role of nonionic surfactants in enhancing cefotaxime drug solubility: a UV-visible spectroscopic investigation in single and mixed micellar formulations. Pharmaceuticals (Basel). 2023;16(12):1663. doi: 10.3390/ph16121663, PMID 38139790.
7. Patil D, Mahajan M, Mahajan A, Viswanadh M, Paradkar A. Soluplus-based pharmaceutical formulations: recent advances in drug delivery and biomedical applications. Future J Pharm Sci. 2024;10(1):54. doi: 10.1186/s43094-024-00639-5.
8. Sa RC, Zeman KL, Bennett WD, Prisk GK, Darquenne C. Effect of posture on regional deposition of coarse particles in the healthy human lung. J Aerosol Med Pulm Drug Deliv. 2015;28(6):423-31. doi: 10.1089/jamp.2014.1189, PMID 25826480.
9. Stavropoulou AP, Theodosiou M, Sakellis E, Boukos N, Papanastasiou G, Wang C. Bimetallic gold-platinum nanoparticles as a drug delivery system coated with a new drug to target glioblastoma. Colloids Surf B Biointerfaces. 2022;214:112463. doi: 10.1016/j.colsurfb.2022.112463, PMID 35316703.
10. Miatmoko A, Ayunin Q, Soeratri W. Ultradeformable vesicles: concepts and applications relating to the delivery of skin cosmetics. Ther Deliv. 2021;12(10):739-56. doi: 10.4155/tde-2021-0044, PMID 34519219.
11. Beck Broichsitter M, Ruppert C, Schmehl T, Gessler T, Seeger W, Kissel T. Development of respirable nanomicelle carriers for the pulmonary delivery of poorly water-soluble drugs: rationale and proof of concept. Mol Pharm. 2015;12(8):2695-707. doi: 10.1021/mp500801q.
12. Chen D, Liu J, Wu J, Suk JS. Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung. Expert Opin Drug Deliv. 2021;18(5):595-606. doi: 10.1080/17425247.2021.1854222, PMID 33218265.
13. Pangeni R, Meng T, Poudel S, Sharma D, Hutsell H, Ma J. Airway mucus in pulmonary diseases: muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers. Int J Pharm. 2023;634:122661. doi: 10.1016/j.ijpharm.2023.122661, PMID 36736964.
14. Huq T, Karim N, Kumar P, Ullah MW, Yang G. Advances in pulmonary drug delivery nanocarriers for respiratory disorders. J Drug Target. 2023;31(2):129-46. doi: 10.1080/1061186X.2022.2139626.
15. Kumar S, Dilbaghi N, Tankeshwar K, Kim KH, Kumar R. Biodegradable mixed polymeric micelles for pulmonary delivery of hydrophobic drugs. J Drug Deliv Sci Technol. 2021;61:102091. doi: 10.1016/j.jddst.2020.102091.
16. Osouli M, Abdollahizad E, Alavi S, Mahboubi A, Abbasian Z, Haeri A. Biocompatible phospholipid-based mixed micelles for posaconazole ocular delivery: development, characterization and in vitro antifungal activity. J Biomater Appl. 2023;37(6):969-78. doi: 10.1177/08853282221141962, PMID 36424544.
17. Ritu G, Suresh R. Development and evaluation of micelle-forming surfactant systems for targeted pulmonary delivery of mucolytics. Int J Curr Pharm Res. 2022;14(1):45-52. doi: 10.22159/ijcpr.2022v14i1.44061.
18. Mahlawat A, Goyal A. Interaction of 3-hydroxy pyridine and surfactant micelles: a fluorescence study. Asian J Pharm Clin Res. 2021;14(8):55-8. doi: 10.22159/ajpcr.2021.v14i8.41895.
19. Tang BC, Dawson M, Lai SK, Wang YY, Suk JS, Yang M. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci USA. 2009;106(46):19268-73. doi: 10.1073/pnas.0905998106, PMID 19901335.
20. Jhaveri AM, Torchilin VP. Multifunctional polymeric micelles for delivery of drugs and siRNA. Front Pharmacol. 2014;5:77. doi: 10.3389/fphar.2014.00077, PMID 24795633.
21. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-24. doi: 10.1038/s41573-020-0090-8, PMID 33277608.
22. Thanki K, Papai K, Parola C, Van Der Paer L, De Ruysscher D, Hart LL. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery. Adv Drug Deliv Rev. 2020;164-165:65-85. doi: 10.1016/j.addr.2019.12.002.
23. Emad H, Nazar Abd Alhammid S. Improvement of the solubility and dissolution characteristics of risperidone via nanosuspension formulations. IJPS 2022 Jun 9;31(1):43-56. doi: 10.31351/vol31iss1pp43-56.
24. Lai SK, Wang YY, Hanes J. Mucus penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158-71. doi: 10.1016/j.addr.2008.11.002, PMID 19133304.
25. Sawant RR, Torchilin VP. Polymeric micelles: polyethylene glycol-phosphatidylethanolamine (PEG-PE)-based micelles as an example. Methods Mol Biol. 2010;624:131-49. doi: 10.1007/978-1-60761-609-2_9, PMID 20217593.
26. Halah Talal Sulaiman, Nawal A Rajab. Preparation and characterization of olmesartan medoxomil-loaded polymeric mixed micelle nanocarrier. Iraqi J Pharm Sci. 2025 Feb 15;33(4SI):89-100. doi: 10.31351/vol33iss(4SI)pp89-100.
27. Manjappa AS, Kumbhar PS, Patil AB, Disouza JI, Patravale VB. Polymeric mixed micelles: improving the anticancer efficacy of single-copolymer micelles. Crit Rev Ther Drug Carrier Syst. 2019;36(1):1-58. doi: 10.1615/CritRevTherDrugCarrierSyst.2018020481, PMID 30806205.
28. Chaudhary S, Mehta A, Mandal A, Patel BM. Formulation strategies and biomedical applications of mixed micelles: emerging trends and future perspectives. Drug Deliv Transl Res. 2023;13(2):377-94. doi: 10.1007/s13346-022-01211-y.
29. Sato H, Yamada K, Miyake M, Onoue S. Recent advancements in the development of nanocarriers for mucosal drug delivery systems to control oral absorption. Pharmaceutics. 2023;15(12):2708. doi: 10.3390/pharmaceutics15122708, PMID 38140049.
30. Dabholkar RD, Sawant RM, Mongayt DA, Devarajan PV, Torchilin VP. Development and evaluation of vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate–mixed polymeric phospholipid micelles of berberine as an anticancer nanopharmaceutical. Drug Deliv. 2016;23(2):547-55. doi: 10.3109/10717544.2014.931726.
31. Bernabeu E, Cagel M, Lagomarsino E, Moretton MA, Chiappetta DA. Paclitaxel-loaded Soluplus and TPGS mixed micelles: a role for cyclodextrin in monomeric drug solubilization and in controlled release to tumors. Colloids Surf B Biointerfaces. 2016;141:403-11. doi: 10.1016/j.colsurfb.2016.01.003.
32. Hou X, Ai X, Liu Z, Yang J, Wu Y, Zhang D. Wheat germ agglutinin modified mixed micelles overcome the dual barrier of mucus/enterocytes for effective oral absorption of shikonin and gefitinib. Drug Deliv Transl Res. 2025;15(1):325-42. doi: 10.1007/s13346-024-01602-0, PMID 38656402.
33. Roe T, Talbot T, Terrington I, Johal J, Kemp I, Saeed K. Physiology and pathophysiology of mucus and mucolytic use in critically ill patients. Crit Care. 2025;29(1):68. doi: 10.1186/s13054-025-05286-x, PMID 39920835.
34. Gupta R, Wadhwa R. Mucolytic Medications. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559163/. PMID: 32644589.
35. Zanasi A, Mazzolini M, Kantar A. A reappraisal of the mucoactive activity and clinical efficacy of Bromhexine. Multidiscip Respir Med. 2017;12:7. doi: 10.1186/s40248-017-0088-1, PMID 28331610.
36. Ensign LM, Tang BC, Wang YY, Tse TA, Hoen T, Cone R. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med. 2012;4(138):138ra79. doi: 10.1126/scitranslmed.3003453, PMID 22700955.
37. Feng X, Chen Y, Li L, Zhang Y, Zhang L, Zhang Z. Preparation evaluation and metabolites study in rats of novel amentoflavone loaded TPGS/Soluplus mixed nanomicelles. Drug Deliv. 2020;27(1):137-50. doi: 10.1080/10717544.2019.1709920, PMID 31913733.
38. Zhao L, Huang Y, Gao Y, Liu L, Liu X, Cao F. Inhalable cationic micelles for pulmonary delivery of siRNA targeting inflammatory cytokines in acute lung injury. J Control Release. 2022;349:798-812. doi: 10.1016/j.jconrel.2022.07.037.
39. Kumar R, Nagarajan R. A comparative study on micelles liposomes and solid lipid nanoparticles drug delivery systems for doxorubicin. Curr Drug Discov Technol. 2022;19(2):31-50. doi: 10.2174/1570163819666220308111232.
40. Song H, Cao XF, Ruan J, Peng X, Wang J, Wang C. Preparation evaluation and metabolites study in rats of novel amentoflavone-loaded TPGS/Soluplus mixed nanomicelles. Nano Biomed Eng. 2011;3(1):34-41. doi: 10.5101/nbe.v3i1.
41. Zhang H, Yang X, Zhao L, Jiao Y, Liu J, Zhai G. In vitro and in vivo study of baicalin-loaded mixed micelles for oral delivery. Drug Deliv. 2016;23(6):1933-9. doi: 10.3109/10717544.2015.1008705, PMID 25693642.
42. Hu J, Han Y, Zhou J, Liu Y, Ma X, Huang Z. Nebulized surfactant polymer hybrid micelles for improved pulmonary delivery of poorly soluble drugs. Int J Pharm. 2022;618:121622. doi: 10.1016/j.ijpharm.2022.121622.
43. Mazumder A, Dwivedi A, Assawapanumat W, Saeeng R, Sungkarat W, Nasongkla N. In vitro galactose targeted study of RSPP050-loaded micelles against liver hepatocellular carcinoma. Pharm Dev Technol. 2022;27(4):379-88. doi: 10.1080/10837450.2022.2063891, PMID 35388736.
44. Elsayed MM, Cevher E. Nanocarriers-based pulmonary drug delivery systems for management of respiratory diseases. Expert Opin Drug Deliv. 2021;18(7):971-91. doi: 10.1080/17425247.2021.1897087.
45. Usmani OS, Mignot B, Kendall I, Maria RD, Cocconi D, Georges G. Predicting lung deposition of extrafine inhaled corticosteroid containing fixed combinations in patients with chronic obstructive pulmonary disease using functional respiratory imaging: an in silico study. J Aerosol Med Pulm Drug Deliv. 2021;34(3):204-11. doi: 10.1089/jamp.2020.1601, PMID 33052749.
46. Xian X, Cai LL, Li Y, Wang RC, Xu YH, Chen YJ. Neuron secrete exosomes containing miR-9-5p to promote polarization of M1 microglia in depression. J Nanobiotechnology. 2022;20(1):122. doi: 10.1186/s12951-022-01332-w, PMID 35264203.
47. Li J, Wu D, Shen C, Wei H, Zhang Y, Li Y. Pulmonary delivery of cationic mixed micelles co-loaded with dexamethasone and curcumin for treatment of acute lung injury. Eur J Pharm Bio pharm. 2023;188:171-82. doi: 10.1016/j.ejpb.2023.05.011.
48. Chen H, Ru X, Wang H, Liu P, Li G, Cao Y. Construction of a cascade catalyst of nanocoupled living red blood cells for implantable biofuel cell. ACS Appl Mater Interfaces. 2021;13(24):28010-6. doi: 10.1021/acsami.1c01479, PMID 34101422.
49. Alsenousy AH, El Tahan RA, Ghazal NA, Pinol R, Millan A, Ali LM. The anti-obesity potential of superparamagnetic iron oxide nanoparticles against high-fat diet-induced obesity in rats: possible involvement of mitochondrial biogenesis in the adipose tissues. Pharmaceutics. 2022;14(10):2134. doi: 10.3390/pharmaceutics14102134, PMID 36297569.
50. Hosseini FS, Dadashzadeh S, Haeri A. Inhalable nanocarriers for pulmonary delivery of anticancer drugs: pharmacokinetics and therapeutic efficacy. Drug Discov Today. 2022;27(11):2993-3006. doi: 10.1016/j.drudis.2022.08.010.
51. Dean D, Nain AS, Genin GM. Special issue: mechanics of cells and fibers. Acta Biomater. 2023;163:1-6. doi: 10.1016/j.actbio.2023.04.045.
52. Zhang H, Zhao Y, Zhang Y, Hang R, Yao X, Hang R. Exosomes derived from macrophages upon cobalt ion stimulation promote angiogenesis. Colloids Surf B Biointerfaces. 2021;203:111742. doi: 10.1016/j.colsurfb.2021.111742, PMID 33838581.
53. Das S, Saha B, Shahiwala A. Polymeric micelles for mucus-penetrating pulmonary drug delivery: recent advances and emerging trends. Expert Opin Drug Deliv. 2023;20(4):555-71. doi: 10.1080/17425247.2023.2185532.
54. Peng S, Wang W, Zhang R, Wu C, Pan X, Huang Z. Nano-formulations for pulmonary delivery: past present and future perspectives. Pharmaceutics. 2024;16(2):161. doi: 10.3390/pharmaceutics16020161, PMID 38399222.
55. Fernandez Garcia R, Fraguas Sanchez AI. Nanomedicines for pulmonary drug delivery: overcoming barriers in the treatment of respiratory infections and lung cancer. Pharmaceutics. 2024;16(12):1584. doi: 10.3390/pharmaceutics16121584, PMID 39771562.
56. Lavorini F, Corrigan T, Usmani OS. Consistent pulmonary drug delivery with whole lung deposition using the aerosphere inhaler: a review of the evidence. Adv Ther. 2021;38(2):837-50. doi: 10.1007/s12325-020-01588-6.
57. Van Rijt SH, Bein T, Meiners S. Medical nanoparticles for next generation drug delivery to the lungs. Eur Respir J. 2014;44(3):765-74. doi: 10.1183/09031936.00212813, PMID 24791828.
58. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10(2):57. doi: 10.3390/pharmaceutics10020057, PMID 29783687.
59. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral parenteral and pulmonary delivery. Artif Cells Nanomed Biotechnol. 2018;46 Suppl 2:178-88. doi: 10.1080/21691401.2018.1438910.
60. Ahmad N, Ahmad R, Naqvi AA, Alam MA, Ashafaq M, Samim M. Rutin-encapsulated chitosan nanoparticles targeted to lungs using intratracheal instillation for treatment of pulmonary fibrosis. Int J Nanomedicine. 2020;15:4503-16. doi: 10.2147/IJN.S252516.
61. Lee WH, Loo CY, Traini D, Young PM. Nano and micro-based inhaled drug delivery systems for targeting alveolar macrophages. Expert Opin Drug Deliv. 2015;12(6):1009-26. doi: 10.1517/17425247.2015.1039509, PMID 25912721.
62. Bi R, Fan W, Ma G, Wang X, Wang Y, Wu Y. Transferrin modified liposomes for the delivery of vincristine to the brain. J Control Release. 2007;121(1-2):13-20.
63. Oliveira AC, Ribeiro AM, Neves AR, Reis CP, Veiga FJ. Current advances in nanocarrier technology for pulmonary drug delivery. Int J Pharm. 2020;579:119-27.
64. Cipolla D, Gonda I, Chan HK. Liposomal formulations for inhalation. Ther Deliv. 2013;4(8):1047-72. doi: 10.4155/tde.13.71, PMID 23919478.
65. Serevicius T, Skaisgiris R, Dodonova J, Jagintavicius L, Banevicius D, Kazlauskas K. Achieving submicrosecond thermally activated delayed fluorescence lifetime and highly efficient electroluminescence by fine-tuning of the phenoxazine-pyrimidine structure. ACS Appl Mater Interfaces. 2020;12(9):10727-36. doi: 10.1021/acsami.9b21394, PMID 32020805.
66. Fiegel J, Fu J, Hanes J. Poly (ethylene glycol) excipient enhances the topical anti-inflammatory efficacy of budesonide in the murine lung. Pharm Res. 2004;21(12):2319-23. doi: 10.1007/s11095-004-7685-z.
67. Xiao B, Laroui H, Viennois E, Ayyadurai S, Charania MA, Zhang Y. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology. 2014;146(5):1289-300.e1. doi: 10.1053/j.gastro.2014.01.056, PMID 24503126.
68. Bivas Benita M, Zwier R, Junginger HE, Borchard G. Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm. 2005;61(3):214-8. doi: 10.1016/j.ejpb.2005.04.009, PMID 16039104.
69. Kim SH, Jeong JH, Kim TI, Kim SW. Pegylated polyethylenimine for gene delivery to the lung via aerosol. Pharm Res. 2005;22(3):438-45. doi: 10.1007/s11095-004-1886-0.
70. Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A. Fundamentals of pulmonary drug delivery. Respir Med. 2003;97(4):382-7. doi: 10.1053/rmed.2002.1457, PMID 12693798.
71. Desai TR, Wong J, Blanchard J. Intratracheal delivery of nanoparticles in rats for assessment of particle uptake and tissue distribution. J Drug Target. 1997;4(3):183-92. doi: 10.3109/10611869709015822.
72. Forbes B, Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications. Eur J Pharm Biopharm. 2005;60(2):193-205. doi: 10.1016/j.ejpb.2005.02.010, PMID 15939233.
73. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003. doi: 10.1038/nmat3776, PMID 24150417.
74. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004;22(8):969-76. doi: 10.1038/nbt994, PMID 15258594.
75. Ali AA, Hussein AA, Ibrahim IM, Osman S. Nanotechnology in pulmonary drug delivery: current applications and challenges. J Pharm Investig. 2022;52(4):317-32. doi: 10.1007/s40005-022-00566-x.
76. Khan MS, Malik A, Basit A, Abrar A, Mehmood M, Rehman IU. Inhalable nanocarrier systems for respiratory disorders: recent advancements and translational perspectives. Eur J Pharm Sci. 2023;184:106472. doi: 10.1016/j.ejps.2023.106472.
77. Hafeez S, Khalid M, Ahmad N, Ullah A, Naeem N, Imran M. A review on inhalable formulations for treatment of respiratory disorders using nanotechnology based drug delivery approaches. Drug Dev Ind Pharm. 2022;48(6):409-22. doi: 10.1080/03639045.2022.2104040.
78. Shen J, Kim HC, Suh J, Kim MG. Aerosol delivery of nanoparticles in drug and gene delivery. Expert Opin Drug Deliv. 2017;14(6):731-46. doi: 10.1080/17425247.2017.1278857.
79. Rashid AM, Ghareeb MM. Using ionic liquids based surfactant in formulating nimodipine polymeric nanoparticles: a promising approach for improved performance. Iraqi J Pharm Sci. 2025 Mar 29;34(1):203-17. doi: 10.31351/vol34iss1pp203-217.
80. Li T, Gu Y, Yu L, Zhu S, Zhang J, Chen Y. Stimuli-responsive double single-atom catalysts for parallel catalytic therapy. Pharmaceutics. 2023;15(4):1217. doi: 10.3390/pharmaceutics15041217, PMID 37111702.
81. Li H, Zhao X, Ma Y, Zhai G, Li L. Recent advances of pulmonary drug delivery based on nanotechnology. J Drug Target. 2022;30(6):628-40. doi: 10.1080/1061186X.2022.2045995.
82. Zhang Y, Xu C, Wang Y, Tang X. Current perspectives on aerosolized nanocarriers for drug delivery to the lungs. Acta Pharmacol Sin B. 2020;10(9):1538-50. doi: 10.1016/j.apsb.2020.03.003.
83. Shrestha N, Shahbazi MA, Araujo F, Mao S, Maatta AM, Sarmento B. Lactoferrin coated porous silicon nanoparticles for enhanced delivery of inhalable antibiotics. ACS Biomater Sci Eng. 2019;5(7):3241-50. doi: 10.1021/acsbiomaterials.9b00366.
84. Tian Y, Jacobs E, Jones DS, McCoy CP, Wu H, Andrews GP. The design and development of high drug loading amorphous solid dispersion for hot-melt extrusion platform. Int J Pharm. 2020;586:119545. doi: 10.1016/j.ijpharm.2020.119545, PMID 32553496.
85. Zhao Y, Liu J, Ding Y, Zhang X, Fu T, Yuan Y. Development of PLGA-based pulmonary delivery system for controlled release of anti-asthmatic agents. Colloids Surf B Biointerfaces. 2021;197:111366. doi: 10.1016/j.colsurfb.2020.111366.
86. Comba A, Paolone G, Baldi A, Vichi A, Goracci C, Bertozzi G. Effects of substrate and cement shade on the translucency and color of CAD/CAM lithium-disilicate and zirconia ceramic materials. Polymers (Basel). 2022;14(9):1778. doi: 10.3390/polym14091778, PMID 35566944.
87. Patil JS, Sarasija S. Pulmonary drug delivery strategies: a concise systematic review. Lung India. 2012;29(1):44-9. doi: 10.4103/0970-2113.92361, PMID 22345913.
88. Hashemi B, Akram FA, Amirazad H, Dadashpour M, Sheervalilou M, Nasrabadi D. Emerging importance of nanotechnology based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients. J Drug Deliv Sci Technol. 2022;67:102967. doi: 10.1016/j.jddst.2021.102967, PMID 34777586.
89. Corrado PA, Barton GP, Razalan Krause FC, Francois CJ, Chesler NC, Wieben O. Dynamic FDG PET imaging to probe for cardiac metabolic remodeling in adults born premature. J Clin Med. 2021;10(6):1301. doi: 10.3390/jcm10061301, PMID 33809883.
90. Niu M, Tan Y, Guan P, Hovgaard L, Lu Y, Qi J. Enhanced pulmonary absorption of insulin-loaded liposomes by using sodium deoxycholate as a permeation enhancer. Int J Pharm. 2015;478(1-2):408-15. doi: 10.1016/j.ijpharm.2014.11.054.
91. Montazam SH, Salatin S, Alami Milani M, Naderi A, Jelvehgari M. Expert design and desirability function approach for the development of diazepam thermally sensitive rectal gel. Ther Deliv. 2020;11(1):813-30. doi: 10.4155/tde-2019-0078, PMID 31847722.
92. Chen J, Zhang L, Li Y, Wang Z, Huang L, Zhang N. Pluronic F127/TPGS mixed micelles enhance pulmonary delivery of bromhexine in rats. Int J Pharm. 2024;646:122345.
93. Rosenkranz AA, Slastnikova TA. Prospects of using protein engineering for selective drug delivery into a specific compartment of target cells. Pharmaceutics. 2023;15(3):987. doi: 10.3390/pharmaceutics15030987, PMID 36986848.
94. Singh M, Sharma R, Bhatia R, Gupta N, Kaur G, DSPE-PEG/TPGS hybrid micelles improve lung deposition and bioavailability of N-acetylcysteine after intranasal administration in mice. Drug Deliv Transl Res. 2023;13(4):1124-36. doi: 10.1007/s13346-022-01256-z.
95. Xu L, Wu X, Liu H, Dong G, Zhan J, Li G. Effects of combination docetaxel with no treatment to enhance the anti-nasopharyngeal carcinoma efficiency in vitro and in vivo. Eur J Pharm Sci. 2022;178:106281. doi: 10.1016/j.ejps.2022.106281, PMID 35995348.
96. Park Y, Kim H, Lee J, Choi S, Kang D. Pluronic F68/chitosan mixed micelles for inhalable carbocisteine: formulation optimization and guinea-pig deposition study. J Control Release. 2022;349:530-42. doi: 10.1016/j.jconrel.2022.07.009.
97. Zheng D, Bai B, Zhao H, Xu X, Hu N, Wang H. Stimuli-responsive Ca-alginate-based photothermal system with enhanced foliar adhesion for controlled pesticide release. Colloids Surf B Biointerfaces. 2021;207:112004. doi: 10.1016/j.colsurfb.2021.112004, PMID 34339971.
98. Martin L, O Connor P, Gorman EM, Curtin CM. Duffy GP. TPGS-stabilized solid-lipid hybrid micelles improve airway deposition of dornase alfa in a cystic fibrosis mouse model. Mol Pharm. 2021;18(7):2628-39. doi: 10.1021/acs.molpharmaceut.1c00213.
99. Bodke V, Tekade BW, Badekar R, Phalak SD, Kale M. Pulsatile drug delivery systems: the novel approach. Int J Pharm Pharm Sci. 2024;16(2):1-11. doi: 10.22159/ijpps.2024v16i2.49960.
100. Imam SS. Nanoparticles: the future of drug delivery. Int J Curr Pharm Sci. 2023;15(6):8-15. doi: 10.22159/ijcpr.2023v15i6.3076.
101. Xu Q, Ensign LM, Boylan NJ, Schon A, Gong X, Yang JC. Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo. ACS Nano. 2015;9(9):9217-27. doi: 10.1021/acsnano.5b03876, PMID 26301576.
102. Perinelli DR, Cespi M, Lorusso N, Palmieri GF, Bonacucina G, Blasi P. Surfactant self-assembling and critical micelle concentration: one approach fits all? Langmuir. 2020;36(21):5745-53. doi: 10.1021/acs.langmuir.0c00420, PMID 32370512.
103. Zhang Z, Tan S, Feng SS. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials. 2012;33(19):4889-906. doi: 10.1016/j.biomaterials.2012.03.046, PMID 22498300.
104. Owens DE, Peppas NA. Opsonization biodistribution and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93-102. doi: 10.1016/j.ijpharm.2005.10.010, PMID 16303268.
105. Dominguez A, Fernandez A, Gonzalez N, Iglesias E, Montenegro L. Determination of critical micelle concentration of some surfactants by three techniques. J Chem Educ. 1997;74(10):1227-31. doi: 10.1021/ed074p1227.
106. Owen SC, Chan DP, Shoichet MS. Polymeric micelle stability. Nano Today. 2012;7(1):53-65. doi: 10.1016/j.nantod.2012.01.002.
107. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24(1):1-16. doi: 10.1007/s11095-006-9132-0, PMID 17109211.
108. Meng X, Liu J, Yu X, Li J, Lu X, Shen T. Pluronic F127 and D-α-Tocopheryl polyethylene glycol succinate (TPGS) mixed micelles for targeting drug delivery across the blood brain barrier. Sci Rep. 2017;7(1):2964. doi: 10.1038/s41598-017-03123-y, PMID 28592843.
109. Feng X, Chen Y, Li L, Zhang Y, Zhang L, Zhang Z. Preparation evaluation and metabolites study in rats of novel amentoflavone loaded TPGS/Soluplus mixed nanomicelles. Drug Deliv. 2020;27(1):137-50. doi: 10.1080/10717544.2019.1709920, PMID 31913733.
110. Lin TY, Zhu TT, Xun Y, Tao YS, Yang YQ, Xie JL. A novel drug delivery system of mixed micelles based on poly (ethylene glycol)-poly(lactide) and poly(ethylene glycol)-poly(ɛ-caprolactone) for gambogenic acid. Kaohsiung J Med Sci. 2019;35(12):757-64. doi: 10.1002/kjm2.12110, PMID 31433556.
111. Mu L, Elbayoumi TA, Torchilin VP. Mixed micelles made of poly (ethylene glycol)-phosphatidylethanolamine conjugate and d-α-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin. Int J Pharm. 2005;306(1-2):142-9. doi: 10.1016/j.ijpharm.2005.08.026, PMID 16242875.
112. Dong K, Zhang M, Liu Y, Gao X, Wu X, Shi D. Pterostilbene loaded soluplus/poloxamer 188 mixed micelles for protection against acetaminophen-induced acute liver injury. Mol Pharm. 2023;20(2):1189-201. doi: 10.1021/acs.molpharmaceut.2c00881, PMID 36647568.
113. Berlinski A, Spiva J. In vitro characterization of aerosolized albuterol generated by a jet nebulizer and delivered through a heated flow nasal cannula system. Pharmaceuticals (Basel). 2022;15(10):1281. doi: 10.3390/ph15101281, PMID 36297393.
114. Steckel H, Eskandar F. Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. Eur J Pharm Sci. 2003;19(5):443-55. doi: 10.1016/S0928-0987(03)00148-9, PMID 12907295.
115. Sweeney L, McCloskey AP, Higgins G, Ramsey JM, Cryan SA, MacLoughlin R. Effective nebulization of interferon-γ using a novel vibrating mesh. Respir Res. 2019;20(1):66. doi: 10.1186/s12931-019-1030-1, PMID 30943978.
116. Islam N, Gladki E. Dry powder inhalers (DPIs) a review of device reliability and innovation. Int J Pharm. 2008;360(1-2):1-11. doi: 10.1016/j.ijpharm.2008.04.044, PMID 18583072.
117. Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech. 2014;15(2):434-55. doi: 10.1208/s12249-013-0063-x, PMID 24452499.
118. Iwanaga T, Tohda Y, Nakamura S, Suga Y. The Respimat® soft mist inhaler: implications of drug delivery characteristics for patients. Clin Drug Investig. 2019;39(11):1021-30. doi: 10.1007/s40261-019-00835-z, PMID 31377981.
119. Pellosi DS, D Angelo I, Maiolino S, Mitidieri E, D Emmanuele Di Villa Bianca R, Sorrentino R. In vitro/in vivo investigation on the potential of Pluronic® mixed micelles for pulmonary drug delivery. Eur J Pharm Biopharm. 2018;130:30-8. doi: 10.1016/j.ejpb.2018.06.006, PMID 29890256.
120. Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K. Amikacin liposome inhalation suspension for treatment refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective open label randomized study. Am J Respir Crit Care Med. 2018;198(12):1559-69. doi: 10.1164/rccm.201807-1318OC, PMID 30216086.
121. Esmaeili M, Aghajani M, Abbasalipourkabir R, Amani A. Budesonide loaded solid lipid nanoparticles for pulmonary delivery: preparation optimization and aerodynamic behavior. Artif Cells Nanomed Biotechnol. 2016;44(8):1964-71. doi: 10.3109/21691401.2015.1129614, PMID 26758698.
122. Amani A, York P, Chrystyn H, Clark BJ. Evaluation of a nanoemulsion based formulation for respiratory delivery of budesonide by nebulizers. AAPS PharmSciTech. 2010;11(3):1147-51. doi: 10.1208/s12249-010-9486-9, PMID 20652776.
Published
How to Cite
Issue
Section
Copyright (c) 2026 hayder imad jabar, Mowafaq M. Ghareeb
This work is licensed under a Creative Commons Attribution 4.0 International License.